Pan-European Survey on the Under Treatment of Hypercholesterolemia - Full Text View

Pan-European Survey on the Under Treatment of Hypercholesterolemia (CEPHEUS)

This study has been completed.

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00542867

Purpose

The survey try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines, overall and by country.·

Condition
Hypercholesterolemia

Genetics Home Reference related topics: hypercholesterolemia

MedlinePlus related topics: Cholesterol

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective
Official Title:	Pan-European Survey on the Under Treatment of Hypercholesterolemia

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

The number and percentage of patients achieving the LDL-C goals, according to the Third Joint European Task Force guidelines, overall and by country.

Enrollment:	6500
Study Start Date:	January 2006
Study Completion Date:	November 2007

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients had to be on a lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00542867

Sponsors and Collaborators

AstraZeneca

Investigators

Principal Investigator:

M. Hermans

UCL

More Information

Study ID Numbers:	SRP-CB-CRE-2006/01
Study First Received:	October 11, 2007
Last Updated:	November 19, 2007
ClinicalTrials.gov Identifier:	NCT00542867
Health Authority:	Belgium: Federal Agency for Medicinal Products and Health

Keywords provided by AstraZeneca:

Hypercholesterolemia
Third Joint European Task Force guidelines
Survey

Study placed in the following topic categories:

Metabolic Diseases
Hyperlipidemias
Metabolic disorder

Hypercholesterolemia
Dyslipidemias
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on January 15, 2009